OneCell Diagnostics, a genomics-based precision oncology company, raised $16 million in Series A funding.
Celesta Capital led the investment round with participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures.
As part of the investment, Celesta Capital Founding Managing Partner Michael Marks and Nobel Laureate and Celesta Capital Senior Advisor Dr. James Rothman will join the OneCell board of directors.
According to press announcement, OneCell Diagnostics plans to use the fresh funds to advance its vision of democratizing precision oncology through cancer diagnostic testing that is more accessible, actionable, and affordable.
With fresh funds, OneCell Diagnostics also intends to to expand into the U.S. market with its advanced liquid biopsy test, OncoIndx Ikon. The liquid biopsytest detects and analyzes CTCs, which offer rich biomarkers that advance precision diagnosis and treatment of cancer for use cases including, treatment response monitoring, disease progression, recurrence, and more.
In the official press statement, Mohan Uttarwar, CEO and Co-founder of OneCell Diagnostics, stated: “We see a future where everyone has access to high-quality, life-saving cancer testing and this funding is a powerful validation of our vision.”
“By integrating our single-cell multi-omics analytics with next-generation liquid biopsy approaches, we have the opportunity to break new ground in delivering accurate, personalized cancer care worldwide,” added Mohan Uttarwar.
According to the World Health Organization, 20 million people are diagnosed with cancer annually worldwide, and 53.5 million people are alive within five years following a cancer diagnosis.